Dexcom Inc Stock Price, News & Analysis

Dexcom, Inc. (NASDAQ:DXCM) has launched the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System, announced through a new Super Bowl commercial featuring Nick Jonas. The G7 promises to be the most accurate and user-friendly CGM on the market, helping diabetes patients improve their health management without fingersticks. The campaign aims to raise awareness among the 4.8 million insulin-dependent Americans, highlighting how the G7 can lower A1C levels and enhance time in range. Approximately 3.3 million viewers who currently do not use CGM have coverage options, making awareness crucial for better diabetes management.

Mednow Inc. (OTCQX: MDNWF) has launched an enhanced Virtual Diabetes Management program that integrates Dexcom G6 real-time continuous glucose monitoring (rtCGM) supplies and diabetes support services. This program offers convenient home delivery and access to certified diabetes educators and clinical pharmacists for personalized care. Initially available in Ontario and British Columbia from early February, the integration aims to improve accessibility and management for diabetes patients. The partnership with Dexcom aims to leverage their technology to enhance patient care and support effective diabetes management.

DexCom, Inc. (NASDAQ:DXCM) announced its plans to release financial results for the fourth quarter and full year 2022 on February 9, 2023, post market close. The management will discuss the results in a conference call at 4:30 p.m. ET on the same day, which will also be available via webcast. This financial report is crucial for investors and stakeholders to gauge the company's performance in the diabetes care technology sector.

Dexcom, Inc. (NASDAQ: DXCM) announced an expansion of coverage for its Dexcom G6 real-time continuous glucose monitoring (rtCGM) system under the Non-Insured Health Benefits (NIHB) program. This change allows all clients living with type 1 diabetes, beyond the existing restriction for ages 2 to 19, to receive coverage. The initiative aims to improve health outcomes for Indigenous communities, who are disproportionately affected by diabetes, by providing greater access to essential healthcare technology. The Dexcom G6 system aids in better glucose control and reduces the risk of diabetes-related complications.

DexCom, Inc. (NASDAQ: DXCM) has appointed Teri Lawver as the chief commercial officer, a newly created role responsible for global sales, marketing, and customer experience. Ms. Lawver brings over 20 years of leadership experience from Johnson & Johnson, where she successfully grew the immunology business from $11 billion to $16 billion. CEO Kevin Sayer praised her ability to drive growth in the healthcare sector. Ms. Lawver aims to leverage Dexcom's market opportunities and technology to expand the reach of continuous glucose monitoring solutions.

DexCom, Inc. (NASDAQ: DXCM) expects preliminary revenue of at least $815 million for Q4 2022, a 17% increase over the prior year. For the full fiscal year 2022, revenue is anticipated to be around $2.91 billion, up 19%. Looking ahead to 2023, DexCom projects total revenue of $3.35 billion to $3.49 billion, reflecting expected growth of 15% to 20%. The company also aims for a Non-GAAP gross profit margin of 62-63% and an operating margin of approximately 16.5%.

DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, starting at 2:15 PM EST. The presentation will be webcast live and made available for later viewing on the Dexcom Investor Relations website.

DexCom focuses on diabetes management through its innovative continuous glucose monitoring (CGM) systems, serving users globally from its headquarters in San Diego, California.

Dexcom, Inc. (NASDAQ: DXCM) has launched a new Digital Diabetes Care Program in partnership with Green Shield and The Health Depot. This initiative will provide Green Shield plan members access to the Dexcom G6 real-time continuous glucose monitoring (rtCGM) system along with virtual diabetes management support. Benefits include automated product shipments, preferred pricing, direct billing, and co-payment assistance for Dexcom supplies. The program aims to enhance diabetes management and improve health outcomes by providing personalized support and clinical consultations.

Dexcom G7 has received FDA clearance for all diabetes types in individuals aged two and older. This next-generation continuous glucose monitoring (CGM) system boasts an overall MARD of 8.2%, making it the most accurate FDA-cleared CGM. With a 60% smaller, all-in-one wearable design, it offers a 30-minute sensor warmup and a suite of features including real-time connectivity with wearables and an upgraded mobile app. Furthermore, Dexcom's G7 is the number one covered CGM, with many users incurring low out-of-pocket costs.